• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>感染症学雑誌 >Respiratory syncytial virus infection
【24h】

Respiratory syncytial virus infection

机译：呼吸合胞病毒感染

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human respiratory syncytial virus (RSV) is the most common worldwide cause of lower respiratory tract infections (LRI) in infants less than 12 months of age. RSV isolates can be divided into group A and B. In addition, there were many genotypes within each group, and these genotypes have evolved global setting with temporal and geographic clustering. Many cellular genes encoding cytokines and chemokines which are activated by RSV infection has now been focused for the elucidation of pathophysiology of RSV LRI. The prophylaxis against RSV infection by vaccination has been unsuccessful because of its adverse effects. No valuable anti-RSV drugs for clinical use have been yet developed. Therefore RSV LRI has been treated mainly symptomatically. Recently humanized anti-RSV F protein monoclonal antibody was developed and prescribed for prevention in high-risk infants such as premature ones and those with chronic lung and congenital heart diseases. It reduced the incidence of hospitalization significantly.
机译：人类呼吸合胞病毒（RSV）是婴儿少于12个月的婴儿呼吸道感染（LRI）的最常见的全球原因。 RSV分离物可分为A组和B组。此外，每组内有许多基因型，这些基因型在时间和地理聚类中进化了全球环境。编码由RSV感染激活的细胞因子和趋化因子的许多细胞基因现在已经专注于阐明RSV LRI的病理生理学。由于其不良反应，通过疫苗接种的预防对RSV感染无力。已经开发出没有有价值的临床用途药物。因此，RSV LRI主要对症状治疗。最近人源化的抗RSV F蛋白单克隆抗体被开发并规定预防高危婴儿，如早产和患有慢性肺和先天性心脏病的婴儿。它显着降低了住院的发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号